Mast cells play an effector role in innate immunity, allergy, and inflammation. Antigen-mediated activation of mast cells initiates signaling events leading to Ca2+ response and the release of inflammatory and allergic mediators from granules. Diseases associated with deregulated mast cell functions are hard to treat and there is an increasing demand for new therapeutic strategies. Miltefosine (hexadecylphosphocholine) is a new candidate for treatment of mast cell-driven diseases as it inhibits activation of mast cells. It has been proposed that miltefosine acts as a lipid raft modulator through its interference with the structural organization of surface receptors in the cell membrane. However, molecular mechanisms of its action are not fully understood. Here, we report that in antigen-activated bone marrow-derived mast cells (BMMCs), miltefosine inhibits degranulation, reorganization of microtubules, as well as antigen-induced chemotaxis. While aggregation and tyrosine phosphorylation of IgE receptors were suppressed in activated cells pre-treated with miltefosine, overall tyrosine phosphorylation levels of Lyn and Syk kinases, and Ca2+ influx were not inhibited. In contrast, lipid raft disruptor methyl-β-cyclodextrin attenuated the Ca2+ influx. Tagged-miltefosine rapidly localized into the cell interior, and live-cell imaging of BMMCs with labeled intracellular granules disclosed that miltefosine inhibited movement of some granules. Immunoprecipitation and in vitro kinase assays revealed that miltefosine inhibited Ca2+- and diacylglycerol-regulated conventional protein kinase C (cPKC) isoforms that are important for mast cell degranulation. Inhibition of cPKCs by specific inhibitor Ly333531 affected activation of BMMCs in the same way as miltefosine. Collectively, our data suggest that miltefosine modulates mast cells both at the plasma membrane and in the cytosol by inhibition of cPKCs. This alters intracellular signaling pathway(s) directed to microtubules, degranulation, and migration.

Department of Biology of Cytoskeleton Institute of Molecular Genetics Czech Academy of Sciences Prague Czechia

Department of Signal Transduction Institute of Molecular Genetics Czech Academy of Sciences Prague Czechia

Zobrazit více v PubMed

Draber P, Halova I, Polakovicova I, Kawakami T. Signal transduction and chemotaxis in mast cells. Eur J Pharmacol (2016) 778:11–23.10.1016/j.ejphar.2015.02.057 PubMed DOI PMC

Nishida K, Yamasaki S, Ito Y, Kabu K, Hattori K, Tezuka T, et al. FcεRI-mediated mast cell degranulation requires calcium-independent microtubule-dependent translocation of granules to the plasma membrane. J Cell Biol (2005) 170:115–26.10.1083/jcb.200501111 PubMed DOI PMC

Sulimenko V, Dráberová E, Sulimenko T, Macůrek L, Richterová V, Dráber P, et al. Regulation of microtubule formation in activated mast cells by complexes of γ-tubulin with Fyn and Syk kinases. J Immunol (2006) 176:7243–53.10.4049/jimmunol.176.12.7243 PubMed DOI

Hájková Z, Bugajev V, Dráberová E, Vinopal S, Dráberová L, Janáček J, et al. STIM1-directed reorganization of microtubules in activated mast cells. J Immunol (2011) 186:913–23.10.4049/jimmunol.1002074 PubMed DOI

Munoz I, Danelli L, Claver J, Goudin N, Kurowska M, Madera-Salcedo IK, et al. Kinesin-1 controls mast cell degranulation and anaphylaxis through PI3K-dependent recruitment to the granular Slp3/Rab27b complex. J Cell Biol (2016) 215:203–16.10.1083/jcb.201605073 PubMed DOI PMC

Pressman BC. Biological applications of ionophores. Annu Rev Biochem (1976) 45:501–30.10.1146/annurev.bi.45.070176.002441 PubMed DOI

Weller K, Artuc M, Jennings G, Friedrichson T, Guhl S, dos Santos RV, et al. Miltefosine inhibits human mast cell activation and mediator release both in vitro and in vivo. J Invest Dermatol (2009) 129:496–8.10.1038/jid.2009.134 PubMed DOI

Hartmann K, Siebenhaar F, Belloni B, Brockow K, Eben R, Hartmann B, et al. Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. Br J Dermatol (2010) 162:185–90.10.1111/j.1365-2133.2009.09434.x PubMed DOI

Magerl M, Rother M, Bieber T, Biedermann T, Brasch J, Dominicus R, et al. Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. J Eur Acad Dermatol Venereol (2013) 27:363–9.10.1111/j.1468-3083.2012.04689.x PubMed DOI

Dölle S, Hoser D, Rasche C, Loddenkemper C, Maurer M, Zuberbier T, et al. Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis. Allergy (2010) 65:1158–65.10.1111/j.1398-9995.2010.02341.x PubMed DOI

Monge-Maillo B, López-Vélez R. Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. Clin Infect Dis (2015) 60:1398–404.10.1093/cid/civ004 PubMed DOI

Schuster FL, Guglielmo BJ, Visvesvara GS. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol (2006) 53:121–6.10.1111/j.1550-7408.2005.00082.x PubMed DOI

Barratt G, Saint-Pierre-Chazalet M, Loiseau PM. Cellular transport and lipid interactions of miltefosine. Curr Drug Metab (2009) 10:247–55.10.2174/138920009787846332 PubMed DOI

van der Luit AH, Vink SR, Klarenbeek JB, Perrissoud D, Solary E, Verheij M, et al. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther (2007) 6:2337–45.10.1158/1535-7163.MCT-07-0202 PubMed DOI

Maurer M, Magerl M, Metz M, Weller K, Siebenhaar F. Miltefosine: a novel treatment option for mast cell-mediated diseases. J Dermatolog Treat (2013) 24:244–9.10.3109/09546634.2012.671909 PubMed DOI

van Blitterswijk WJ, Verheij M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des (2008) 14:2061–74.10.2174/138161208785294636 PubMed DOI

Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs (2003) 14:167–73.10.1097/00001813-200302000-00011 PubMed DOI

Ward PD, Ouyang H, Thakker DR. Role of phospholipase C-β in the modulation of epithelial tight junction permeability. J Pharmacol Exp Ther (2003) 304:689–98.10.1124/jpet.102.043638 PubMed DOI

Lucas L, Hernández-Alcoceba R, Penalva V, Lacal JC. Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity. Oncogene (2001) 20:1110–7.10.1038/sj.onc.1204216 PubMed DOI

Überall F, Oberhuber H, Maly K, Zaknun J, Demuth L, Grunicke HH. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res (1991) 51:807–12. PubMed

Kovářová M, Tolar P, Arudchandran R, Dráberová L, Rivera J, Dráber P. Structure-function analysis of Lyn kinase association with lipid rafts and initiation of early signaling events after Fcε receptor I aggregation. Mol Cell Biol (2001) 21:8318–28.10.1128/MCB.21.24.8318-8328.2001 PubMed DOI PMC

Tolar P, Tůmová M, Dráber P. New monoclonal antibodies recognizing the adaptor protein LAT. Folia Biol (Praha) (2001) 47:215–7. PubMed

Volná P, Lebduška P, Dráberová L, Šímová S, Heneberg P, Boubelík M, et al. Negative regulation of mast cell signaling and function by the adaptor LAB/NTAL. J Exp Med (2004) 200:1001–13.10.1084/jem.20041213 PubMed DOI PMC

Nováková M, Dráberová E, Schürmann W, Czihak G, Viklický V, Dráber P. γ-Tubulin redistribution in taxol-treated mitotic cells probed by monoclonal antibodies. Cell Motil Cytoskeleton (1996) 33:38–51.10.1002/(SICI)1097-0169(1996)33:1<38::AID-CM5>3.0.CO;2-E PubMed DOI

Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell (1995) 83:301–11.10.1016/0092-8674(95)90171-X PubMed DOI

Heneberg P, Lebduška P, Dráberová L, Korb J, Dráber P. Topography of plasma membrane microdomains and its consequences for mast cell signaling. Eur J Immunol (2006) 36:2795–806.10.1002/eji.200636159 PubMed DOI

Černohorská M, Sulimenko V, Hájková Z, Sulimenko T, Sládková V, Vinopal S, et al. GIT1/βPIX signaling proteins and PAK1 kinase regulate microtubule nucleation. Biochim Biophys Acta (2016) 1863:1282–97.10.1016/j.bbamcr.2016.03.016 PubMed DOI

Hornillos V, Carrillo E, Rivas L, Amat-Guerri F, Acuña AU. Synthesis of BODIPY-labeled alkylphosphocholines with leishmanicidal activity, as fluorescent analogues of miltefosine. Bioorg Med Chem Lett (2008) 18:6336–9.10.1016/j.bmcl.2008.10.089 PubMed DOI

Dráberová E, Sulimenko V, Vinopal S, Sulimenko T, Sládková V, D’Agostino L, et al. Differential expression of human γ-tubulin isotypes during neuronal development and oxidative stress points to a γ-tubulin-2 prosurvival function. FASEB J (2017) 31:1828–46.10.1096/fj.201600846RR PubMed DOI

Sulimenko V, Sulimenko T, Poznanovic S, Nechiporuk-Zloy V, Böhm KJ, Macurek L, et al. Association of brain γ-tubulins with αβ-tubulin dimers. Biochem J (2002) 365:889–95.10.1042/bj20020175 PubMed DOI PMC

Bambousková M, Hájková Z, Dráber P, Dráber P. Microscopy assays for evaluation of mast cell migration and chemotaxis. Methods Mol Biol (2014) 1192:161–76.10.1007/978-1-4939-1173-8_12 PubMed DOI

Dráberová E, Dráber P. A microtubule-interacting protein involved in coalignment of vimentin intermediate filaments with microtubules. J Cell Sci (1993) 106:1263–73. PubMed

Kinet JP. The high-affinity IgE receptor (FcεRI): from physiology to pathology. Annu Rev Immunol (1999) 17:931–72.10.1146/annurev.immunol.17.1.931 PubMed DOI

Surviladze Z, Dráberová L, Kovářová M, Boubelík M, Dráber P. Differential sensitivity to acute cholesterol lowering of activation mediated via the high-affinity IgE receptor and Thy-1 glycoprotein. Eur J Immunol (2001) 31:1–10.10.1002/1521-4141(200101)31:1<1::AID-IMMU1>3.0.CO;2-W PubMed DOI

Yanase Y, Hide I, Mihara S, Shirai Y, Saito N, Nakata Y, et al. A critical role of conventional protein kinase C in morphological changes of rodent mast cells. Immunol Cell Biol (2011) 89:149–59.10.1038/icb.2010.67 PubMed DOI

Lim PS, Sutton CR, Rao S. Protein kinase C in the immune system: from signalling to chromatin regulation. Immunology (2015) 146:508–22.10.1111/imm.12510 PubMed DOI PMC

Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, et al. Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCβ. Bioorg Med Chem Lett (2003) 13:1857–9.10.1016/S0960-894X(03)00286-5 PubMed DOI

Verhaar AP, Wildenberg ME, Peppelenbosch MP, Hommes DW, van den Brink GR. Repurposing miltefosine for the treatment of immune-mediated disease? J Pharmacol Exp Ther (2014) 350:189–95.10.1124/jpet.113.212654 PubMed DOI

Verweij J, Planting A, van der Burg M, Stoter G. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. J Cancer Res Clin Oncol (1992) 118:606–8.10.1007/BF01211805 PubMed DOI

Pachioni Jde A, Magalhães JG, Lima EJ, Bueno Lde M, Barbosa JF, de Sá MM, et al. Alkylphospholipids – a promising class of chemotherapeutic agents with a broad pharmacological spectrum. J Pharm Pharm Sci (2013) 16:742–59.10.18433/J3CW23 PubMed DOI

Vukman KV, Metz M, Maurer M, O’Neill SM. Isolation and culture of bone marrow-derived mast cells. Bio-Protocol (2014) 4:e1053.10.21769/BioProtoc.1053 DOI

Ruschmann J, Antignano F, Lam V, Snyder K, Kim C, Essak M, et al. The role of SHIP in the development and activation of mouse mucosal and connective tissue mast cells. J Immunol (2012) 188:3839–50.10.4049/jimmunol.1003875 PubMed DOI PMC

Matsushima H, Yamada N, Matsue H, Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol (2004) 173:531–41.10.4049/jimmunol.173.1.531 PubMed DOI

Dráberová L, Lebduška P, Hálová I, Tolar P, Štokrová J, Tolarová H, et al. Signaling assemblies formed in mast cells activated via Fcε receptor I dimers. Eur J Immunol (2004) 34:2209–19.10.1002/eji.200322663 PubMed DOI

Holowka D, Baird B. Roles for lipid heterogeneity in immunoreceptor signaling. Biochim Biophys Acta (2016) 1861:830–6.10.1016/j.bbalip.2016.03.019 PubMed DOI PMC

Altman A, Kong KF. Protein kinase C inhibitors for immune disorders. Drug Discov Today (2014) 19:1217–21.10.1016/j.drudis.2014.05.008 PubMed DOI PMC

Verma NK, Dey CS. The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro. Diabetologia (2006) 49:1656–60.10.1007/s00125-006-0260-1 PubMed DOI

Kim MS, Rådinger M, Gilfillan AM. The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol (2008) 29:493–501.10.1016/j.it.2008.07.004 PubMed DOI PMC

Linke M, Fritsch SD, Sukhbaatar N, Hengstschläger M, Weichhart T. mTORC1 and mTORC2 as regulators of cell metabolism in immunity. FEBS Lett (2017) 591:3089–103.10.1002/1873-3468.12711 PubMed DOI PMC

Ramsay DB, Stephen S, Borum M, Voltaggio L, Doman DB. Mast cells in gastrointestinal disease. Gastroenterol Hepatol (N Y) (2010) 6:772–7. PubMed PMC

Blank U, Rivera J. The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol (2004) 25:266–73.10.1016/j.it.2004.03.005 PubMed DOI

Regulation of microtubule nucleation in mouse bone marrow-derived mast cells by ARF GTPase-activating protein GIT2

Mast Cell Migration and Chemotaxis Assayed by Microscopy

Regulation of Microtubule Nucleation in Mouse Bone Marrow-Derived Mast Cells by Protein Tyrosine Phosphatase SHP-1